The safety and efficacy of the administration of recombinant activated factor VII in major surgery and trauma patients

By Wilson Stephen J   Bellamy Mark C   Giannoudis Peter V  

Expert Opinion on Drug Safety, Vol. 4, Iss. 3, 2005-05 ,pp. : 557-570

Informa Healthcare

Access to resources Recommend Favorite

Eptacog-alfa [activated recombinant factor VII] is an effective, well-tolerated therapy in haemophilia patients with inhibitors

By  

Inpharma, Vol. 1, Iss. 1572, 2007-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Determinants of Drug Costs in Hospitalised Patients with Haemophilia: Impact of Recombinant Activated Factor VII

By Galanaud J.P.  

PharmacoEconomics, Vol. 21, Iss. 10, 2003-01 ,pp. : 699-707

Adis International

Access to resources Recommend Favorite

Management of bleeding emergencies: when to use recombinant activated Factor VII

By DeLoughery Thomas G  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 1, 2006-01 ,pp. : 25-34

Informa Healthcare

Access to resources Recommend Favorite

Uncontrolled Bleeding in Surgical Patients: The Role of Recombinant Activated Factor VIIa

By  

Current Drug Targets, Vol. 10, Iss. 8, 2009-08 ,pp. : 744-770

Bentham Science Publishers

Access to resources Recommend Favorite